Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular Carcinoma
- The companies collaborated to evaluate the safety, tolerability, PK, PD & preliminary antitumor activity of OTX-2002 as monotx. & in combination with Roche’s atezolizumab in the P-I/II trial (MYCHELANGELO I) for MYC-driven HCC & other solid tumor types
- Roche will be responsible to supply atezolizumab and Omega will evaluate the combination as part of the overall conduct of the trial
- Anti-PD-1 & anti-PD-L1 immune checkpoint inhibitors which are used as SoC treatments for HCC showed synergistic antitumor activity with OTX-2002 in preclinical studies with minimal impact on safety & tolerability. The preliminary results from the monotx. dose escalation portion of the study is expected in 2023
Ref: omega therapeutics | Image: omega therapeutics
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.